Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verdiperstat in Semantic Variant Primary Progressive Aphasia (svPPA)
NCT05184569Phase 1Active, not recruiting
- Start
- Apr 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in semantic variant primary progressive aphasia (svPPA) comparing Verdiperstat with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
verdiperstat
03
Conditions
semantic variant primary progressive aphasia (svPPA)
Beyond the preview
Go deeper on NCT05184569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184569.